A first-to-market, guideline-backed neuromodulation therapy hits a 2026 reimbursement inflection—if NRXS outruns dilution, the upside can be dramatic.
Overview
NeurAxis (NRXS) is a commercial-stage medtech/bioscience company focused on proprietary neuromodulation for chronic GI-related pain conditions, with initial commercial traction in Disorders of Gut-Brain Interaction (DGBI). Its revenue engine is **IB‑Stim**, a first-to-market FDA-cleared, wearable, behind-the-ear neuromodulator using Percutaneous Electrical Nerve Field Stimulation (PENFS) to modulate cranial nerve bundles and reduce visceral pain signaling along the gut-brain axis. The therapy is drug-free and non-surgical, positioned against a flawed standard of care reliant on off-label psychiatric drugs with significant side effects, especially in pediatrics. The model is inherently recurring: a standard course uses a disposable device worn for 120 hours, replaced weekly across four weeks; recent labeling allows **up to four devices per patient**, enhancing per-patient economics. NeurAxis expanded beyond a narrow adolescent niche through sequential FDA clearances, now covering ages 8–21 and, critically, securing an October 2025 adult FD pain + nausea clearance that opens a much larger TAM. The company also commercializes RED (Rectal Expulsion Device), an FDA-cleared point-of-care diagnostic for constipation-related evacuation disorders, leveraging the same gastroenterology call points. Commercial execution depends heavily on reimbursement and workflow adoption: payer coverage expanded dramatically to ~55M covered lives by late 2025, clinical guidelines incorporated PENFS as a recommended therapy (JPGN), and an AMA Category I CPT code took effect Jan 1, 2026—collectively intended to move IB‑Stim from early adoption to scalable routine use. Despite very high gross margins (~83%+), the company is still loss-making and funding growth via equity raises, making 2026 conversion to breakeven scale the pivotal investment question.